Exeltis: THX Pharma and Exeltis announce first milestone achieved for neurological disease treatment

THX Pharma (Theranexus), a pharma company focusing on developing treatments for rare neurological disease, and Exeltis, a pharma company within the Insud Pharma group, have announced that the first milestone has been achieved in their licence and supply agreement for TX01, a treatment for rare neurological diseases. TX01 is a novel formulation of an already [...] The post THX Pharma and Exeltis announce first milestone achieved for neurological disease treatment appeared first on Pharmafile.